Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel, Oxaliplatin and Fluorouracil for Gastric Cancer With Peritoneal Carcinomatosis and Inoperable Malignant Bowel Obstruction
NCT04840264Phase 2Recruiting
- Sponsor
- The Sixth Affiliated Hospital of Sun Yat-Sen University
- Start
- Jan 2022
- Primary completion
- Dec 2027
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of docetaxel, oxaliplatin, fluorouracil in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, peritoneal carcinomatosis (PC), malignant bowel obstruction (MBO), sponsored by The Sixth Affiliated Hospital of Sun Yat-Sen University. Started Jan 2022; status: recruiting.
02
Drugs
docetaxeloxaliplatinfluorouracil
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomaperitoneal carcinomatosis (PC)malignant bowel obstruction (MBO)
Beyond the preview
Go deeper on NCT04840264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04840264.